论文部分内容阅读
目的 探讨基质金属蛋白酶 - 9(matrixmetalloproteinase - 9,MMP - 9)在乳腺浸润性导管癌组织中的表达及临床意义。方法 应用免疫组化SP法检测 12 0例乳腺浸润性导管癌患者中MMP - 9的表达。结果 12 0例乳腺癌患者中 ,阳性表达 92例 ,占 76 6 7% ,其中高表达 48例 ,占 40 %。MMP - 9的表达与乳腺癌的PCNA表达、TNM分期、淋巴结状况、肿瘤大小相关 ,与年龄、月经状况、ER表达无关。结论 MMP - 9的表达 ,可以作为估计乳腺浸润性导管癌预后及术后综合治疗的生物学指标。
Objective To investigate the expression and clinical significance of matrix metalloproteinase - 9 (MMP - 9) in invasive ductal carcinoma of breast. Methods Immunohistochemical SP method was used to detect the expression of MMP - 9 in 120 breast invasive ductal carcinomas. Results Among 120 cases of breast cancer, 92 cases were positive, accounting for 76.6%, of which 48 cases were highly expressed (40%). The expression of MMP - 9 was correlated with PCNA expression, TNM stage, lymph node status and tumor size in breast cancer, but not with age, menstrual status and ER expression. Conclusions The expression of MMP - 9 can be used as a biological index to estimate the prognosis of breast invasive ductal carcinoma and postoperative comprehensive treatment.